Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Operations: 2009-2025

Historic Cash from Operations for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to -$236,987.

  • China Pharma Holdings' Cash from Operations fell 404.74% to -$236,987 in Q3 2025 from the same period last year, while for Sep 2025 it was $201,107, marking a year-over-year increase of 127.66%. This contributed to the annual value of -$500,000 for FY2024, which is 28.54% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Cash from Operations is -$236,987, which was down 180.81% from $293,258 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Cash from Operations peaked at $1.0 million during Q3 2023, and registered a low of -$1.5 million during Q1 2023.
  • In the last 3 years, China Pharma Holdings' Cash from Operations had a median value of -$60,000 in 2025 and averaged -$109,401.
  • As far as peak fluctuations go, China Pharma Holdings' Cash from Operations surged by 1,017.60% in 2024, and later crashed by 404.74% in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Cash from Operations stood at -$198,112 in 2021, then skyrocketed by 395.08% to $584,594 in 2022, then crashed by 103.82% to -$22,323 in 2023, then surged by 1,017.60% to $204,836 in 2024, then plummeted by 404.74% to -$236,987 in 2025.
  • Its last three reported values are -$236,987 in Q3 2025, $293,258 for Q2 2025, and -$60,000 during Q1 2025.